Assessing covalent binding of reactive drug metabolites by complete protein digestion and LC-MS analysis

Bioanalysis

Volumn 2, Issue 7, 2010, Pages 1211-1221

  Mitrea, Nicoleta ^a   Leblanc, André ^a   St Onge, Maude ^a   Sleno, Lekha ^a  

^a UNIVERSITÉ DU QUÉBEC À MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; CYSTEINE; DICLOFENAC; DRUG METABOLITE; ESTRADIOL; FIPEXIDE; PARACETAMOL; PRONASE; DRUG; IMMOBILIZED ENZYME; PROTEIN;

ACCURACY; AMINO ACID ANALYSIS; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; COVALENT BOND; DISSOCIATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENZYME IMMOBILIZATION; HYDROPHOBICITY; IN VITRO STUDY; INTERMETHOD COMPARISON; LIQUID CHROMATOGRAPHY; MOLECULAR STABILITY; NONHUMAN; PROCESS DEVELOPMENT; PROTEIN DEGRADATION; RAT; TANDEM MASS SPECTROMETRY; ANIMAL; HUMAN; MASS SPECTROMETRY; METABOLISM; METHODOLOGY; MICROSOME; PROTEIN BINDING;

AMINO ACIDS; ANIMALS; CHROMATOGRAPHY, LIQUID; ENZYMES, IMMOBILIZED; HUMANS; MASS SPECTROMETRY; MICROSOMES; PHARMACEUTICAL PREPARATIONS; PRONASE; PROTEIN BINDING; PROTEINS; RATS;

EID: 79952468004     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.10.74     Document Type: Article

References (31)

1. Zhou S, Chan E, Duan W, Huang M, Chen Y-Z. Drug bioactivation, covalent binding to target proteins and toxicity relevance. Drug Metab. Rev. 37, 41-213 (2005). (Pubitemid 40259715)
2. Uetrecht J. Idiosyncratic drug reactions: past, present and future. Chem. Res. Toxicol. 21, 84-92 (2008). (Pubitemid 351219710)
3. Evans DC, Watt AP, Nicoll-Griffith DA, Baillie TA. Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem. Res. Toxicol. 17, 3-16 (2004). (Pubitemid 38134055)
4. Day SH, Mao A, White R, Schultz-Utermoehl T, Miller R, Beconi MG. A semi-automated method for measuring the potential for protein covalent binding in drug discovery. J. Pharmacol. Toxicol. Methods 52, 278-285 (2005). (Pubitemid 41207205)
5. Bauman JN, Kelly JM, Tripathy S et al. Can in vitro metabolism-dependent covalent binding data distinguish hepatotoxic from non-hepatotoxic drugs? An analysis using human hepatocytes and liver S-9 fraction. Chem. Res. Toxicol. 22, 332-340 (2009).
6. Ma S, Subramanian R. Detecting and characterizing reactive metabolites by liquid chromatography/tandem mass spectrometry. J. Mass Spectrom. 41, 1121-1139 (2006). (Pubitemid 44454166)
7. Ma S, Zhu M. Recent advances in applications of liquid chromatography-tandem mass spectrometry to the analysis of reactive drug metabolites. Chem. Biol. Interact. 179, 25-37 (2009).
8. Ikehata K, Duzhak TG, Galeva NA, Ji T, Koen YM, Hanzlik RP. Protein targets of reactive metabolites of thiobenzamide in rat liver in vivo. Chem. Res. Toxicol. 21, 1432-1442 (2008).
9. Helleberg H, Törnqvist M. A new approach for measuring protein adducts from benzo[a] pyrene diolepoxide by high performance liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 14, 1644-1653 (2000).
10. Bambal RB, Hanzlik RP. Bromobenzene 3,4-oxide alkylates histidine and lysine side chains of rat liver proteins in vivo. Chem. Res. Toxicol. 8, 729-735 (1995).
11. Ding A, Zia-Amirhosseini P, McDonagh AF, Burlingame AL, Benet LZ. Reactivity of tolmetin glucuronide with human serum albumin. Identification of binding sites and mechanisms of reaction by tandem mass spectrometry. Drug Metab. Dispos. 23, 369-376 (1995).
12. Cohen SA, Michaud DP. Synthesis of a fluorescent derivatizing reagent 6-aminoquinolyl-N-hydroxysuccinimidyl carbamate, and its application for the analysis of hydrolysate amino acids via high performance liquid chromatography. Anal. Biochem. 211, 279-287 (1993). (Pubitemid 23207730)
13. Rutherford SM, Gilani GS. Amino acid analysis. Curr. Protoc. Protein Sci. 58, 11.9.1-11.9.37 (2009).
14. Noort D, van Zuylen A, Fidder A, van Ommen B, Hulst AG. Protein adduct formation by glucuronide metabolites of permethrin. Chem. Res. Toxicol. 21, 1396-1406 (2008).
15. Cabras T, Fanali C, Monteiro JA et al. Tyrosine polysulfation of human salivary Histatin 1. A post-translational modification specific of the submandibular gland. J. Proteome Res. 6, 2472-2480 (2007). (Pubitemid 47122343)
16. Yike I, Distler AM, Ziady AG, Dearborn DG. Mycotoxin adducts on human serum albumin: biomarkers of exposure to Stachybotrys chartarum. Environ. Health Perspect. 114, 1221-1226 (2006). (Pubitemid 44184680)
17. Delatour T, Fenaille F, Parisod V et al. A comparative study of proteolysis methods for the measurement of 3-nitrotyrosine residues: enzymatic digestion versus hydrochloric acid-mediated hydrolysis. J. Chromatogr. B 851, 268-276 (2007). (Pubitemid 46729684)
18. Bessems JG, Vermeulen NP. Paracetamol (acetaminophen)-induced toxicity: molecular and biochemical mechanisms, analogues and protective approaches. Crit. Rev. Toxicol. 31, 55-138 (2001). (Pubitemid 32157805)
19. Prescott L. Paracetamol: past, present, and future. Am. J. Ther. 7, 143-147 (2000).
20. Bartolone JB, Sparks K, Cohen SD, Khairallah EA. Immunochemical detection of acetaminophen-bound liver proteins. Biochem. Pharmacol. 36, 1193-1196 (1987). (Pubitemid 17083171)
21. Potter WZ, Thorgeirsson SS, Jollow DJ, Mitchell JR. Acetaminophen-induced hepatic necrosis. V. Correlation of hepatic necrosis, covalent binding and glutathione depletion in hamsters. Pharmacology 12, 129-143 (1974).
22. Hoos JS, Damsten MC, de Vlieger JSB et al. Automated detection of covalent adducts to human serum albumin by immunoaffinity chromatography, on-line solution phase digestion and liquid chromatography-mass spectrometry. J. Chromatogr. B 859, 147-156 (2007). (Pubitemid 350046443)
23. Lohmann W, Hayen H, Karst U. Covalent protein modification by reactive drug metabolites using online electrochemistry/ liquid chromatography/mass spectrometry. Anal. Chem. 80, 9714-9719 (2008).
24. Damsten MC, Commandeur JNM, Fidder A et al. Liquid chromatography/tandem mass spectrometry detection of covalent binding of acetaminophen to human serum albumin. Drug Metab. Disp. 35, 1408-1417 (2007). (Pubitemid 47121783)
25. Durand F, Samuel D, Bernuau J et al. Fipexide-induced fulminant hepatitis. Report of three cases with emergency liver transplantation. J. Hepatol. 15, 144-146 (1992).
26. Guy C, Blay N, Rousset H, Fardeau V, Ollagnier M. Fever caused by fipexide. Evaluation of the national pharmacovigilance survey. Therapie 45, 429-431 (1990). (Pubitemid 20345748)
27. Sleno L, Staack RF, Varesio E, Hopfgartner G. Investigating the in vitro metabolism of fipexide: characterization of reactive metabolites using liquid chromatography/mass spectrometry. Rapid Commun. Mass Spectrom. 21, 2301-2311 (2007). (Pubitemid 47121162)
28. Sleno L, Varesio E, Hopfgartner G. Determining protein adducts of fipexide: mass spectrometry based assay for confirming the involvement of its reactive metabolite in covalent binding. Rapid Commun. Mass Spectrom. 21, 4149-4157 (2007).
29. Boelsterli UA. Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity. Toxicol. Appl. Pharmacol. 192, 307-322 (2003). (Pubitemid 37311346)
30. Raftogianis R, Creveling C, Weinshilboum R, Weisz J. Estrogen metabolism by conjugation. J. Natl Cancer Inst. Monogr. 27, 113-124 (2000).
31. 5-dependent: metabolic activation of the ethynyl moiety leads to the formation of glutathione conjugates, a heme adduct, and covalent binding to the apoprotein. J. Pharmacol. Exp. Ther. 321, 276-287 (2007) (Pubitemid 46456978)